Schwab Charles Investment Management Inc. Has $510.25 Million Stake in Amgen Inc. (AMGN)

Schwab Charles Investment Management Inc. increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 2.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,962,595 shares of the medical research company’s stock after buying an additional 67,815 shares during the period. Schwab Charles Investment Management Inc. owned 0.41% of Amgen worth $510,248,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Waldron LP acquired a new position in Amgen during the first quarter valued at approximately $444,000. Argyle Capital Management Inc. raised its position in Amgen by 0.6% during the first quarter. Argyle Capital Management Inc. now owns 30,584 shares of the medical research company’s stock valued at $5,018,000 after purchasing an additional 168 shares in the last quarter. Benedict Financial Advisors Inc. raised its position in Amgen by 3.5% during the first quarter. Benedict Financial Advisors Inc. now owns 22,346 shares of the medical research company’s stock valued at $3,666,000 after purchasing an additional 764 shares in the last quarter. Moloney Securities Asset Management LLC raised its position in Amgen by 23.5% during the first quarter. Moloney Securities Asset Management LLC now owns 8,306 shares of the medical research company’s stock valued at $1,363,000 after purchasing an additional 1,578 shares in the last quarter. Finally, KAMES CAPITAL plc raised its position in Amgen by 14.7% during the first quarter. KAMES CAPITAL plc now owns 15,023 shares of the medical research company’s stock valued at $2,465,000 after purchasing an additional 1,929 shares in the last quarter. Institutional investors own 78.08% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Schwab Charles Investment Management Inc. Has $510.25 Million Stake in Amgen Inc. (AMGN)” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://ledgergazette.com/2017/10/21/schwab-charles-investment-management-inc-has-510-25-million-stake-in-amgen-inc-amgn.html.

Several research analysts have commented on AMGN shares. Deutsche Bank AG started coverage on shares of Amgen in a research report on Friday, June 23rd. They set a “hold” rating and a $172.00 price objective for the company. BidaskClub upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 23rd. William Blair restated a “market perform” rating on shares of Amgen in a research report on Monday, June 26th. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $189.00 price objective on shares of Amgen in a research report on Friday, June 30th. Finally, ValuEngine upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. Twelve research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $189.94.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction on Monday, October 9th. The shares were sold at an average price of $185.95, for a total value of $283,573.75. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.19% of the stock is owned by company insiders.

Shares of Amgen Inc. (NASDAQ:AMGN) opened at 182.96 on Friday. The company has a market cap of $133.50 billion, a PE ratio of 16.66 and a beta of 1.36. The firm’s 50-day moving average is $185.13 and its 200-day moving average is $171.60. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $191.10.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. The company had revenue of $5.81 billion for the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm’s revenue was up 2.1% compared to the same quarter last year. During the same quarter last year, the company earned $2.84 EPS. On average, equities research analysts predict that Amgen Inc. will post $12.58 earnings per share for the current year.

Amgen Profile

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Waldron LP acquired a new position in Amgen during the first quarter valued at approximately $444,000. Argyle Capital Management Inc. raised its position in Amgen by 0.6% during the first quarter. Argyle Capital Management Inc. now owns 30,584 shares of the medical research company’s stock valued at $5,018,000 after purchasing an additional 168 shares in the last quarter. Benedict Financial Advisors Inc. raised its position in Amgen by 3.5% during the first quarter. Benedict Financial Advisors Inc. now owns 22,346 shares of the medical research company’s stock valued at $3,666,000 after purchasing an additional 764 shares in the last quarter. Moloney Securities Asset Management LLC raised its position in Amgen by 23.5% during the first quarter. Moloney Securities Asset Management LLC now owns 8,306 shares of the medical research company’s stock valued at $1,363,000 after purchasing an additional 1,578 shares in the last quarter. Finally, KAMES CAPITAL plc raised its position in Amgen by 14.7% during the first quarter. KAMES CAPITAL plc now owns 15,023 shares of the medical research company’s stock valued at $2,465,000 after purchasing an additional 1,929 shares in the last quarter. Institutional investors own 78.08% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Schwab Charles Investment Management Inc. Has $510.25 Million Stake in Amgen Inc. (AMGN)” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://ledgergazette.com/2017/10/21/schwab-charles-investment-management-inc-has-510-25-million-stake-in-amgen-inc-amgn.html.

Several research analysts have commented on AMGN shares. Deutsche Bank AG started coverage on shares of Amgen in a research report on Friday, June 23rd. They set a “hold” rating and a $172.00 price objective for the company. BidaskClub upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 23rd. William Blair restated a “market perform” rating on shares of Amgen in a research report on Monday, June 26th. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $189.00 price objective on shares of Amgen in a research report on Friday, June 30th. Finally, ValuEngine upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. Twelve research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $189.94.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction on Monday, October 9th. The shares were sold at an average price of $185.95, for a total value of $283,573.75. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.19% of the stock is owned by company insiders.

Shares of Amgen Inc. (NASDAQ:AMGN) opened at 182.96 on Friday. The company has a market cap of $133.50 billion, a PE ratio of 16.66 and a beta of 1.36. The firm’s 50-day moving average is $185.13 and its 200-day moving average is $171.60. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $191.10.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. The company had revenue of $5.81 billion for the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm’s revenue was up 2.1% compared to the same quarter last year. During the same quarter last year, the company earned $2.84 EPS. On average, equities research analysts predict that Amgen Inc. will post $12.58 earnings per share for the current year.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply